Palatin's Board of Directors
Carl Spana, Ph.D.
President, Chief Executive Officer and Director
Dr. Spana is a co-founder of Palatin, and has been our Chief Executive Officer and President since June 2000, and from June 1996 through 2000 was our executive vice president and chief technical officer. Previously Dr. Spana was vice president of Paramount Capital Investments, LLC, a biotechnology and biopharmaceutical merchant banking firm, and of The Castle Group Ltd., a medical venture capital firm. From 1991 to 1993, Dr. Spana was a Research Associate at Bristol-Myers Squibb where he was involved in scientific research in the field of immunology.
John K.A. Prendergast, Ph.D.
Chairman of the Board
Dr. Prendergast is a co-founder of Palatin, and has been Chairman of the board since 2000 and a director since 1996. Dr. Prendergast is president of Summercloud Bay, Inc., an independent consulting firm providing services to the biotechnology industry, and a director and executive chairman of the board of directors of Antyra, Inc., a privately-held biopharmaceutical firm. From 1991 through 1997 he was a managing director of The Castle Group Ltd., a medical venture capital firm. Dr. Prendergast is a director and executive chairman of the board of directors of Antyra, Inc., a privately held biopharmaceutical firm, and a director of Heart Biologics, Inc., a publicly traded clinical stage immunotherapy company.
Dr. Prendergast received his M.Sc. and Ph.D. from the University of New South Wales, Sydney, Australia and a C.S.S. in administration and management from Harvard University.
Robert K. deVeer, Jr.
Mr. deVeer has been a director since 1998. Since 1997 he has been the president of deVeer Capital LLC, a private investment company. From 1995 until his retirement in 1996, Mr. deVeer served as Managing Director, Head of Industrial Group, at New York-based Lehman Brothers. From 1973 to 1995, he held increasingly responsible positions at New York-based CS First Boston, including Head of Project Finance, Head of Industrials and Head of Natural Resources. He was a managing director, member of the investment banking committee and a trustee of the First Boston Foundation.
Mr. deVeer received a B.A. in economics from Yale University and an M.B.A. in finance from Stanford Graduate School of Business.
J. Stanley Hull
Mr. Hull has been a director since 2005. He has over three decades of experience in the field of sales and marketing. Mr. Hull joined GlaxoSmithKline, a research-based pharmaceutical company, in 1987 and retired as Senior Vice President, Pharmaceuticals in 2010, having previously served in the R&D organization of Glaxo Wellcome as Vice President and Worldwide Director of Therapeutic Development and Product Strategy – Neurology and Psychiatry. Prior to that, he was Vice President of Marketing – Infectious Diseases and Gastroenterology for Glaxo Wellcome. Mr. Hull started his career in the pharmaceutical industry with SmithKline and French Laboratories in 1978.
Mr. Hull received his B.S. in business administration from the University of North Carolina at Greensboro.
Alan W. Dunton, M.D.
Dr. Dunton has been a director since 2011. Since November 2015, he has been senior vice president of research and development for Purdue Pharma L.P., with responsibilities for overall research strategy and development programs. He founded Danerius, LLC, a biotechnology consulting company, in 2006. From 2007 to 2009, Dr. Dunton served as president and chief executive officer of Panacos Pharmaceuticals Inc. and served as managing director of Panacos from 2009 to 2011. Dr. Dunton has extensive experience serving on the board of directors of publicly traded companies. From 1994 to 2001, Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson.
Dr. Dunton received his M.D. degree from New York University School of Medicine, where he completed his residency in internal medicine. He also was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center.
Ms. Rossetti has been a director since 2013. From June 2015 through July 2017 she served as Executive Vice President of Cell Machines, an early stage biopharmaceutical company developing novel protein therapies. Previously, Ms. Rossetti served in pharmaceutical marketing, communications and financial roles, including as Vice President at Pfizer Inc., where she led a global commercial medicine team for smoking cessation, and as an Assistant Vice President at Wyeth, managing a global hemophilia business. She also served as President of Ogilvy Healthworld, an advertising business in the pharmaceutical and biotechnology sectors, and on the Biotech and Pharmaceutical Advisory Board of Danske Capital for six years.
Ms. Rossetti graduated from a joint program of the Albert Einstein College of Medicine and Benjamin N. Cardozo School of Law with an M.S.in Bioethics in 2014, and has an M.B.A. in Finance from Columbia University Graduate School of Business and a B.A. in Biology from the University of Pennsylvania.
Arlene M. Morris
Ms. Morris has been a director since June 2015. Since May 2015 she has served as the chief executive officer of Willow Advisors, LLC. From March 2012 until May 2015 she was Chief Executive Officer of Syndax Pharmaceuticals, Inc., a privately held biopharmaceutical company focused on the development and commercialization of an epigenetic therapy for treatment-resistant cancers. From 2003 to January 2011, Ms. Morris served as the President, Chief Executive Officer and a member of the board of directors of Affymax, Inc., a publicly traded biotechnology company. Ms. Morris has also held various management and executive positions at Clearview Projects, Inc., a corporate advisory firm, Coulter Pharmaceutical, Inc., a publicly traded pharmaceutical company, Scios Inc., a publicly traded biopharmaceutical company, and Johnson & Johnson, a publicly traded healthcare company. She is currently a member of the board of directors of Viveve Medical, Inc., a publicly traded female healthcare medical device company, Dimension Therapeutics, Inc., a publicly traded gene therapy company, and Neovacs, SA, a French publicly traded biotechnology company, and was a director of Biodel Inc., a publicly traded specialty pharmaceutical company, from 2015 until its merger with Albireo Limited in 2016..
Ms. Morris received a B.A. in Biology and Chemistry from Carlow College.
Anthony M. Manning, Ph.D.
Dr. Manning has been a director of Palatin since September 2017. Since 2013, he has been senior vice president of research at Momenta Pharmaceuticals, Inc., a publicly traded biopharmaceutical company developing therapeutics for autoimmune indications, biosimilars and generic versions of complex drugs. From 2011 to 2013, he was senior vice president of research and development at Aileron Therapeutics, Inc., a publicly traded biopharmaceutical company developing stapled peptide therapeutics for cancers and other diseases. From 2007 to 2011, he was vice president and head of inflammation and autoimmune diseases research at Biogen, Inc., a publicly traded biopharmaceutical company developing medicines for neurological and neurodegenerative conditions. From 2002 to 2007, he was vice president and global therapy area head for Roche Pharmaceuticals, the pharmaceutical division of Roche Holding AG, and from 2000 to 2002 he was vice president of Pharmacia, a global pharmaceutical company acquired by Pfizer in 2002.
Dr. Manning received his Ph.D., M.Sc. and B.Sc. from the University of Otago, Dunedin, New Zealand.